Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | MTTP | P55157 | 8/20 | 0.44 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.43 |
| ▸ | APOB | P04114 | 4/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808934 | 0.92 | SMO (0.52) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6803201 | 0.90 | HTR2A (0.49) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6805251 | 0.90 | SMO (0.50) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6803858 | 0.89 | SMO (0.52) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6804211 | 0.89 | HTR2A (0.48) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6801953 | 0.89 | SMO (0.52) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6804688 | 0.88 | SMO (0.61) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6804573 | 0.87 | SMO (0.51) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6805026 | 0.85 | HTR2C (0.51) | SMOHTR2AHTR2CHTR2BMTTP | |
| SCHEMBL6804505 | 0.85 | SMO (0.52) | SMOHTR2AHTR2CHTR2BMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1383760-A1 | BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | SMO 4390/4885HTR2A 2176/4885HTR2C 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.